International sales increased 52%, including an 11% favorable foreign
exchange impact, to $169 million in the fourth quarter of 2007 from
$111 million in the same period in 2006 primarily due to increased
demand in Latin America and Europe.
-- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse
transcriptase inhibitor for the treatment of HIV, increased 17%,
including a 5% favorable foreign exchange impact, to $260 million in
the fourth quarter of 2007 from $222 million in the same period in
2006. U.S. sales increased 13% to $162 million in the fourth quarter
of 2007 from $144 million in the same period in 2006, primarily due to
higher demand of ATRIPLA(TM). Estimated total U.S. prescription demand
increased approximately 15% compared to 2006. International sales
increased 26%, including a 13% favorable foreign exchange impact, to
$98 million in the fourth quarter of 2007 from $78 million in the same
period in 2006. Total revenue for the SUSTIVA(R) Franchise includes
sales of SUSTIVA(R), as well as revenue from bulk efavirenz included in
the combination therapy ATRIPLA(TM), which is sold through a joint
venture in the U.S. and Canada with Gilead Sciences, Inc.
-- Sales of BARACLUDE(R), an oral antiviral agent for the treatment of
chronic hepatitis B, increased 175%, including a 13% favorable foreign
exchange impact, to $99 million in the fourth quarter of 2007 from $36
million in the same period in 2006, due to continued growth across all
markets.
-- Sales of ORENCIA(R), a fusion protein indicated for adult patients with
moderate to severe rheumatoid arthritis launched in 2006, increased
134%, including a 3% favorable foreign exchange impact, to $75 million,
in the fourth quarter of 2007 from $32 million in the
'/>"/>
| SOURCE Bristol-Myers Squibb Company Copyright©2008 PR Newswire. All rights reserved |